Amgen's Romiplostim Shows Breakthrough Results for Chemotherapy-Induced Thrombocytopenia with NCCN Endorsement
Key Insights
Amgen's romiplostim demonstrated significant efficacy in a phase 3 trial, reducing chemotherapy dose modifications in 84% of patients with chemotherapy-induced thrombocytopenia compared to 36% with placebo (p<0.001).
The National Comprehensive Cancer Network (NCCN) has included romiplostim in its 2025 guidelines as a recommended treatment for patients with persistent chemotherapy-induced thrombocytopenia.
Patients treated with romiplostim achieved platelet recovery 10 days faster than placebo, with median nadir platelet counts reaching 87×10⁹/L versus 58×10⁹/L in the control group.
Amgen's romiplostim has emerged as a potential game-changer in oncology supportive care following compelling phase 3 trial results and endorsement from the National Comprehensive Cancer Network (NCCN). The thrombopoietin receptor agonist demonstrated significant efficacy in treating chemotherapy-induced thrombocytopenia (CIT), a condition affecting up to 30% of cancer patients that forces treatment delays and dose reductions.
Phase 3 Trial Delivers Strong Results
The pivotal phase 3 trial enrolled 165 patients with gastrointestinal cancers, including colorectal, gastroesophageal, and pancreatic malignancies. Results presented at this year's ASCO conference showed romiplostim reduced chemotherapy dose modifications caused by low platelets in 84% of patients, compared to just 36% in the placebo group—a statistically significant difference (p<0.001).
Patients receiving romiplostim achieved platelet recovery 10 days faster than those on placebo, with median nadir platelet counts reaching 87×10⁹/L versus 58×10⁹/L in the control group. The trial reported no new serious adverse events beyond what was previously documented in prior studies.
NCCN Guidelines Provide Clinical Validation
The NCCN's inclusion of romiplostim in its 2025 guidelines represents a pivotal milestone for the drug's clinical adoption. The guidelines now recommend romiplostim for patients with persistent CIT despite standard therapies, providing oncologists with a clear, evidence-based treatment pathway for a condition that has long lacked effective options.
"The NCCN's stamp of approval is the ultimate validation," said Dr. Lisa Lacayo, a hematologist-oncologist at the Mayo Clinic. "This isn't just a niche therapy—it's a tool that could fundamentally change how we manage chemotherapy toxicity."
Addressing Critical Unmet Medical Need
CIT represents a significant clinical challenge, characterized by dangerously low platelet counts that can force dose reductions, delays, or discontinuations of life-saving cancer treatments. Current treatment options—platelet transfusions and older agents like eltrombopag—fall short of meeting patient needs. Platelet transfusions require costly hospital visits, carry infection risks, and often fail to sustain adequate platelet counts.
The demand for effective platelet-boosting agents is expected to surge as global cancer cases are projected to rise by 45% by 2040, according to the World Health Organization, with increasing reliance on aggressive myelosuppressive therapies like FOLFOX (search) and FOLFIRI (search) regimens.
Market Opportunity and Financial Implications
Analysts estimate the global CIT market could exceed $2.5 billion by 2030, with romiplostim positioned to capture significant market share given its first-mover advantage backed by NCCN guidelines and ASCO credibility. Projections suggest romiplostim's CIT sales could reach $800 million annually by 2027, potentially climbing higher if the drug gains broader approvals for other cancers or patient populations.
The drug's existing label for chronic immune thrombocytopenia (ITP) already generates robust revenue for Amgen, and its supportive care profile aligns with the company's strategic shift toward oncology-focused growth.
Ongoing Clinical Development
Amgen continues to expand romiplostim's clinical evidence through the PROCLAIM study, a phase 3 randomized, placebo-controlled, double-blind trial evaluating the drug's efficacy in patients with non-small cell lung cancer, ovarian cancer, or breast cancer receiving chemotherapy. The study, which began recruitment in February 2020 and was updated in July 2025, employs quadruple masking to ensure robust data integrity.
The comprehensive clinical program underscores Amgen's commitment to establishing romiplostim as the standard of care across multiple cancer types, potentially expanding its addressable patient population and market opportunity beyond gastrointestinal malignancies.